Antibody-drug conjugates for ovarian cancer with poor response to platinum therapy
Official title: Antibody-drug conjugates for the Treatment of Ovarian Cancer with a Suboptimal Response to Platinum-based Neoadjuvant Therapy
Funded at Mayo Clinic Rochester · NIH-11421328 · Data updated 2026-11-12
A Mayo Clinic team is testing targeted antibody-drug conjugates to help people with advanced high-grade ovarian cancer who did not respond well to standard platinum-based treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | July 1, 2009 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $273,432 |
| NIH project number | 2P50CA136393-16 |
| Project ID | NIH-11421328 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with high-grade serous ovarian cancer (or related peritoneal cancers) who showed suboptimal response to platinum-based neoadjuvant therapy.
✕Less likely to help
Patients whose disease is already responding well to standard therapy or who cannot tolerate antibody-drug conjugates may not benefit.
What this research studies
This project focuses on patients with high-grade serous ovarian cancer who have suboptimal responses to neoadjuvant platinum therapy. Researchers are exploring antibody-drug conjugates that deliver potent cancer-killing drugs directly to tumor cells, aiming to improve tumor shrinkage and survival. The study builds on biomarkers that identify poor responders and uses TOP1-inhibiting ADCs to overcome resistance. The approach blends prior clinical signals with lab data to select promising treatment strategies for difficult-to-treat patients.
Why it matters
Potential benefit: If successful, patients with resistant ovarian cancer could experience better responses and longer, healthier lives.
How similar studies have gone: Other TOP1-inhibiting ADCs have shown activity in platinum-resistant ovarian cancer, suggesting potential benefit with this approach.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Knutson, Keith L. — Mayo Clinic Rochester
- Study coordinator: Knutson, Keith L.
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.